Alpco Home Page
New: Calprotectin Immunoturbidimetric Assay will take your testing to the next level. Learn more.Supporting your work with life science and clinical testing productsVIEW ALL LIFE SCIENCE PRODUCTSVIEW ALL CLINICAL DIAGNOSTIC PRODUCTS
Responsibility
ALPCO’s Diabetes Research Travel GrantALPCO strives to provide scientists and healthcare professionals with robust tools for their research and clinical diagnostic endeavors. We understand that championing extraordinary discoveries requires extraordinary efforts, and support. We are proud to continu...
Clinical Research
New: Calprotectin Immunoturbidimetric Assay will take your testing to the next level. Learn more.ALPCO has been serving the needs of clinical researchers and clinical diagnostics labs for over 30 years, and we now offer a broad product menu of proprietary automated sample-to-answer platforms. We’re ...
AACC 2023
Skip the crowd and reserve your time for a demonstration or individual meeting with a member of our team.Stop by Booth #2547
Ask About Our Targeted Solutions for Your GI Testing.Customized solutions for your calprotectin testing needs.GI SOLUTIONSEnsure AccuracyNew! Calprotectin Immunoturbidimetric...
New Stool-Based Gastroenterology Assays and Extraction Method Can Improve Lab Sample Processing Time By Up To 86%
Date: January 26, 2016
ALPCO recently launched a new panel of 13 stool-based gastroenterology assays that are all compatible with one single extraction step. The unique extraction method allows laboratories to improve their sample processing time by up to 86% by extracting one sample for up to 13...
Stool-Based Biomarkers to Differentiate Between IBD and IBS
What are IBD and IBS?
Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are two different gastrointestinal tract issues affecting millions of people every day. Although there is some overlap between symptoms of IBD and IBS, differences still remain in regards to pathologies, risks...
New Zonulin ELISAs and Therapeutic Drug Monitoring Assays for IBD to be Launched at Digestive Disease Week®
We are excited to announce that we will launch new gastrointestinal and inflammatory bowel disease (IBD) assays at Digestive Disease Week® May 7-9, 2017 in Chicago, IL. Included in this release are the Zonulin Stool ELISA and Zonulin Serum ELISA to aid in the study of gut permeability and celiac dis...
Featured Biomarkers from A to Z
This handout briefly describes the role of several important hormones measured in research.
Differentiating Gastrointestinal Pathogens from IBD and IBS
Gastrointestinal (GI) disorders such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), as well as infections from GI pathogens can present very similar symptoms. A host of tests have been developed to aid in the differentiation between IBD and IBS, such as calprotectin and lact...
Toxicology
Drug-Induced Organ Injury
Toxicological side effects are a common obstacle in drug development pipelines and often manifest in site-specific damage to vital organs, including the liver, kidney and heart. Estimates of compound attrition from failure to meet safety endpoints are as high as 45% in pre...
Heart Disease Biomarkers in Diabetes Research
Introduction
Cardiovascular disease (CVD) encompasses a constellation of diseases related to the heart and circulatory system. Despite efforts to understand and combat CVD complications from diabetes, 65% of diabetics will pass away from cardiovascular issues1. Part 2 of The Common Denominator eBoo...
Physiological Actions of Natriuretic Peptides
Introduction
Humans have at least 50 discovered hormones managing vital biological functions in the body. These hormones are produced by the body’s organs and glands. Natriuretic peptides (NPs) are structurally related hormones synthesized and released from the heart, including atrial natriuretic p...
Early Detection of Diabetic Kidney Disease with Biomarkers
Introduction
Over one third of diabetics will develop diabetic kidney disease (DKD) in their lifetime1. Despite the large amount of diabetics suffering from DKD, current methods for measuring and tracking kidney function may not be specific enough for diabetic systems2,3.
Part III of The Common ...
De-escalating Inflammatory Bowel Disease Therapies
Date: June 21, 2016
Author: Andrea Tarbet, Product Marketing Associate at ALPCO
Several therapies exist to help treat inflammatory bowel disease (IBD) and improve patient quality of life. However, a growing number of gastroenterologists and patients have been choosing to stop these therapies -...
Emerging Biomarker Research in NAFLD and NASH
Nonalcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disease in the western hemisphere affecting 1 in 3 adults and 1 in 10 children1. Today, liver biopsies are the only gold standard for precise diagnosis of NAFLD2. Because of this, there are tremendous efforts on the ...
ALPCO to Exhibit at the AACC’s 70th Annual Scientific Meeting and Clinical Lab Expo
July 25, 2018
ALPCO will exhibit at the AACC’s 70th Annual Clinical Lab Expo July 31-August 2, 2018 in Chicago, IL. The company will promote a number of tools to help research and improve clinical outcomes as well as increase laboratory efficiency.
Among these tools are new and upcoming additi...
ALPCO Announces Inaugural Young Investigators Award Recipient
October 17, 2018
ALPCO has announced the first recipient of its new young investigators award, the Diabetes Research Travel Grant. The grant was created to help advance progressive diabetes and obesity research by graduate students, postdoctoral fellows, and early stage investigators. The program...
The Relationship Between Glucagon and Energy Homeostasis
Glucagon is a gut hormone generated as a result of post translational modifications during proglucagon processing in the pancreas1,2,3. Research has demonstrated that glucagon has many physiological functions1,4. Understanding the role of glucagon in energy homeostasis has become important to many d...
Now Available: 510(k) Cleared Fecal Calprotectin ELISA
ALPCO received 510(k) clearance from the US FDA for its new fecal Calprotectin Chemiluminescence ELISA test.
The ALPCO Calprotectin Chemiluminescence ELISA’s superior clinical accuracy will enable clinical laboratories to provide the most accurate results to gastroenterologists facing the cha...
Why Clinical Specificity is Important for FDA Cleared Fecal Calprotectin Tests
The Importance of Clinical Specificity: A Review of FDA Cleared Fecal Calprotectin Tests
Download
Selecting the right fecal calprotectin test for your clinical laboratory to run in-house or send out can be a difficult task to accomplish, especially when there are multiple FDA cleared options...
ALPCO’s Calprotectin Validation Assistance Program
Whether your clinical laboratory is transitioning over to the ALPCO Calprotectin Chemiluminescence ELISA from another calprotectin assay or starting to run the test in-house for the first time, validation is the most crucial step in the assay implementation process. We understand that validating a n...
Managing Calprotectin as a Send Out?
While sending out for calprotectin testing offers some cost and convenience advantages when volumes are very low, bringing the process in-house allows for the opportunity to control costs, turnaround time, and quality. Considering costs and potential revenue, the volume at which in-house calprotecti...
Enhance Your Lab’s Molecular GI Portfolio
Molecular GI testing for bacteria such as salmonella, vibrio, and E. coli, and viral pathogens including norovirus and rotavirus, is instrumental in the diagnosis and treatment of infection and dysbiosis. In addition, many gastrointestinal disorders often require protein biomarker tests to aid in ac...
GI Testing
Calprotectin Chemiluminescence ELISA (80-CALPHU-CH01)
The Calprotectin Chemiluminescence ELISA is an in vitro diagnostic chemiluminescent assay intended for the quantitative measurement of fecal calprotectin, a neutrophilic protein that is a marker of intestinal mucosal inflammation, in human sto...